Who are SUCLEAR®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BF-200 ALA cream, Ameluz 10% Topical Gel, TOOKAD VTP, Physician's Choice SOC, NDL-PDT, MAL 16.8% cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/suclear.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SUCLEAR® — Competitive Intelligence Brief

SUCLEAR® (SUCLEAR®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photodynamic therapy agent. Area: Oncology.

phase 3 Photodynamic therapy agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SUCLEAR® (SUCLEAR®) — National Cancer Center, Korea. SUCLEAR is a photodynamic therapy agent that generates reactive oxygen species upon light activation to selectively destroy cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SUCLEAR® TARGET	SUCLEAR®	National Cancer Center, Korea	phase 3	Photodynamic therapy agent
BF-200 ALA cream	BF-200 ALA cream	Joint Authority for Päijät-Häme Social and Health Care	marketed	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer generated from aminolevulinic acid)
Ameluz 10% Topical Gel	Ameluz 10% Topical Gel	Psoriasis Treatment Center of Central New Jersey	marketed	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer)
TOOKAD VTP	TOOKAD VTP	Steba Biotech S.A.	marketed	Photodynamic therapy agent	Vascular endothelial cells (non-receptor mediated phototoxicity)
Physician's Choice SOC	Physician's Choice SOC	Rakuten Medical, Inc.	phase 3	X-ray activated photodynamic therapy agent
NDL-PDT	NDL-PDT	Galderma R&D	phase 3	Photodynamic therapy agent
MAL 16.8% cream	MAL 16.8% cream	Galderma R&D	phase 3	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photodynamic therapy agent class)

Galderma R&D · 3 drugs in this class
DUSA Pharmaceuticals, Inc. · 2 drugs in this class
Biofrontera Bioscience GmbH · 2 drugs in this class
Steba Biotech S.A. · 2 drugs in this class
National Cancer Center, Korea · 1 drug in this class
Photocure · 1 drug in this class
Psoriasis Treatment Center of Central New Jersey · 1 drug in this class
Joint Authority for Päijät-Häme Social and Health Care · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SUCLEAR® — Competitive Intelligence Brief. https://druglandscape.com/ci/suclear. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab